At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
Rosuvastatin 10 mg. daily for 96 weeks +1 moredrug
Likely dose
Rosuvastatin 10 mg. daily for 96 weeksfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation
University Hospitals Cleveland Medical Center·interventional·Posted Oct 11, 2010·Updated Mar 8, 2016
In Brief
A Phase 2 clinical trial evaluating Rosuvastatin 10 mg. daily for 96 weeks and Placebo for HIV Infections and Heart Disease. Completed, enrolled 147 participants across 1 site.
Detailed Summary
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Heart Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), AstraZeneca
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartFeb 2011
Primary CompletionMay 2014
TodayJul 2026
First PostedOct 11, 2010
Enrollment StartFeb 1, 2011
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.7 years ago
Interventions
Rosuvastatin 10 mg. daily for 96 weeksdrug
Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
Placebodrug
participants will take a sugar pill daily for 96 weeks